Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer
Barbara E. Kahn(William P. Wharton Trust), Natasha Kyprianou(Icahn School of Medicine at Mount Sinai)
Cited by 110
Related Papers
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
|Cancer Research|2010|350
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer
|The Prostate|2006|87
Novel Pharmacologic Targeting of Tight Junctions and Focal Adhesions in Prostate Cancer Cells
|PLoS ONE|2014|35